Reaction mass of 2-ethylhexyl diphenyl phosphite and bis(2-ethylhexyl) phenyl phosphite and triphenyl phosphite

Endpoint summary

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion

Endpoint conclusion:

adverse effect observed (sensitising)

Additional information:

Based on both the results of the key study and supporting data from analog substances (triphenyl phosphite (TPP), diisodecyl phenyl phosphite (DDPP) , diphenyl isodecyl phosphite (DPDP)), 2 -EHDPP is expected to be a skin sensitiser. Given the lower responses levels at the 15% v/v concentration compared to the 30% v/v concentration, it does not appear that 2 -EHDPP would be a strong sensitiser. This is further supported by the less than conclusive results from the DPDP GPMT and the fact that DDPP had an EC3 concentration of 40% in a recent LLNA study.

Migrated from Short description of key information:
There are both skin sensitisation studies on 2-EHDPP and several on close phosphite analogs, diphenyl isodecyl phosphite (DPDP) and triphenyl phosphite (TPP) and diisodecyl phenyl phosphite (DDPP). The guinea pig maximisation study of 2-EHDPP showed positive responses in 8 of the 10 test animals at the 30% v/v challenge concentration. The responses were lower at the lower (15% v/v) challenge concentration. The study authors concluded that this substance is a skin sensitiser. These data are further supported by positive LLNA studies on related phosphites.

Justification for classification or non-classification

2 -EHDPP is classified as a skin sensitiser based on test data.